- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00873496
Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients
March 31, 2009 updated by: Ege University
Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients: a Prospective Sample Study.
Chronic inflammation that comprises the exocrine glands' function leads to xerophthalmia and xerostomia in Sjögren's syndrome.
The oral consequences range widely and they are related to decreased salivary output.
Hydroxychloroquine may inhibit cholinesterase activity in salivary glands via interference with antigen processing mechanism, and thus, the investigators' hypothesis was that salivary gland function may be improved if treated with hydroxychloroquine.
The effects of hydroxychloroquine on the salivary flow rate, subjective and objective parameters of the patients were also assessed.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Bornova
-
Izmir, Bornova, Turkey, 35100
- Ege University School of Dentistry
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Probability Sample
Study Population
The study group consisted of 30 female patients recently diagnosed as Sjögren's syndrome.
Description
Inclusion Criteria:
- Patients who were recently diagnosed with primary SS according to American-European criteria and who were scheduled for HCQ treatment in Ege University Faculty of Medicine, Department of Rheumatology
Exclusion Criteria:
- Sjögren patients consuming alcohol or tobacco
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Sjögren
Pre and post treatment establishment of salivary flow rate, objective and subjective clinical oral complications' severity of the patients using hydroxychloroquine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Salivary flow rate, objective and subjective clinical oral complaints
Time Frame: 2005 Jan-2009 Jan
|
2005 Jan-2009 Jan
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Esin Alpoz, Ege University School of Dentistry
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Alpoz E, Guneri P, Onder G, Cankaya H, Kabasakal Y, Kose T. The efficacy of Xialine in patients with Sjogren's syndrome: a single-blind, cross-over study. Clin Oral Investig. 2008 Jun;12(2):165-72. doi: 10.1007/s00784-007-0159-3. Epub 2007 Nov 14.
- Kruize AA, Hene RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, Bijlsma JW. Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993 May;52(5):360-4. doi: 10.1136/ard.52.5.360.
- Dawson LJ, Caulfield VL, Stanbury JB, Field AE, Christmas SE, Smith PM. Hydroxychloroquine therapy in patients with primary Sjogren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford). 2005 Apr;44(4):449-55. doi: 10.1093/rheumatology/keh506. Epub 2004 Dec 8.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2005
Primary Completion (Actual)
October 1, 2008
Study Completion (Actual)
January 1, 2009
Study Registration Dates
First Submitted
March 31, 2009
First Submitted That Met QC Criteria
March 31, 2009
First Posted (Estimate)
April 1, 2009
Study Record Updates
Last Update Posted (Estimate)
April 1, 2009
Last Update Submitted That Met QC Criteria
March 31, 2009
Last Verified
March 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Eye Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Stomatognathic Diseases
- Mouth Diseases
- Lacrimal Apparatus Diseases
- Arthritis, Rheumatoid
- Salivary Gland Diseases
- Dry Eye Syndromes
- Sjogren's Syndrome
- Xerostomia
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Hydroxychloroquine
Other Study ID Numbers
- EAlpoz 1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Xerostomia
-
University of BrasiliaNot yet recruitingXerostomia Following Radiotherapy
-
Bedford Hospital NHS TrustUnknownXerostomia | Xerostomia Due to Radiotherapy | Xerostomia Due to Hyposecretion of Salivary Gland
-
Poznan University of Medical SciencesEnrolling by invitationXerostomia Due to Hyposecretion of Salivary GlandPoland
-
MeiraGTx, LLCActive, not recruitingRadiation-induced XerostomiaUnited States, Canada
-
Thomas KuhntVerband Deutscher DruckkammerzentrenTerminatedRadiation-induced XerostomiaGermany
-
Laboratoires CARILENEDERMSCAN-PHARMASCAN GROUP in charge of data analysisCompleted
-
Alexandria UniversityRecruitingRadiation Induced XerostomiaEgypt
-
Institute of Oncology LjubljanaUniversity Medical Centre Ljubljana; University of Ljubljana; Blood Transfusion...Not yet recruitingXerostomia Following RadiotherapySlovenia
-
Catholic University of the Sacred HeartSunstar Italiana SRL.CompletedXerostomia | Xerostomia Following RadiotherapyItaly
Clinical Trials on Hydroxychloroquine
-
Cambridge University Hospitals NHS Foundation TrustUnknown
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnMyelodysplastic Syndromes | Progressive DiseaseUnited States
-
Health Institutes of TurkeyCompleted
-
Peng Wang, MD PhDCompleted
-
University of MichiganCures Within ReachTerminatedRetinitis PigmentosaUnited States
-
University Hospital, MontpellierTerminatedCoronavirus Infection | Pneumonia, ViralFrance
-
Kunming Pharmaceuticals, Inc.Not yet recruiting
-
Hospital do CoracaoHospital Israelita Albert Einstein; Hospital Sirio-Libanes; Brazilian Research... and other collaboratorsCompletedCoronavirus InfectionsBrazil
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedLymphangioleiomyomatosisUnited States
-
Ravi Amaravadi, MDTerminatedCOVID-19United States